- Home
- ANGH vs MBRX Comparison
ANGH vs MBRX Comparison
Compare ANGH & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGH | MBRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 23.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ANGH | MBRX |
|---|---|---|
| Price | $2.65 | $4.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 8.9K | ★ 300.6K |
| Earning Date | 04-30-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,093,405.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 88.72 | N/A |
| 52 Week Low | $2.46 | $4.75 |
| 52 Week High | $8.88 | $91.25 |
Technical Indicators
Market Signals| Indicator | ANGH | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.69 | 61.39 |
| Support Level | $2.50 | $4.75 |
| Resistance Level | $3.00 | $7.98 |
| Average True Range (ATR) | 0.13 | 0.59 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 11.11 | 60.11 |
Price Performance
Historical ComparisonAbout ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.